What is the interpretation of the liver function test results showing total bilirubin 0.9 mg/dL, direct bilirubin 0.3 mg/dL, AST 61 U/L, ALT 142 U/L, alkaline phosphatase 178 U/L, albumin 3.6 g/dL, and globulin 3.1 g/dL?

Hepatocellular Pattern of Liver Injury with Mild Cholestatic Component

These liver function tests demonstrate a predominantly hepatocellular pattern of injury (ALT 142 U/L with ALT > AST) with a mild cholestatic component (ALP 178 U/L), normal synthetic function, and minimal bilirubin elevation—most consistent with metabolic dysfunction-associated steatotic liver disease (MASLD), medication/supplement-induced hepatotoxicity, or viral hepatitis.

Pattern Recognition

Your results show:

• Hepatocellular predominance: ALT (142 U/L) is elevated more than 3-4× normal for females or ~2.5× for males, with ALT > AST ratio of 2.3:1, indicating hepatocyte injury rather than cholestasis 1, 2
• Mild cholestatic component: ALP (178 U/L) is mildly elevated, suggesting some biliary involvement but not the primary process 3
• Preserved synthetic function: Albumin 3.6 g/dL (low-normal) and normal bilirubin indicate intact hepatic synthetic capacity 3
• Minimal hyperbilirubinemia: Total bilirubin 0.9 mg/dL with direct 0.3 mg/dL is essentially normal, ruling out significant cholestasis or hepatocellular failure 2

Immediate Clinical Assessment Required

Obtain detailed history focusing on:

• Metabolic risk factors: BMI, diabetes, hypertension, dyslipidemia (MASLD is the most common cause of chronic aminotransferase elevation) 2
• All medications and supplements: Prescription drugs, over-the-counter medications, herbal products, vitamins—these are frequently overlooked causes 1, 2
• Alcohol consumption: Quantify precisely in grams/day (AST/ALT ratio < 1 argues against alcohol as primary cause) 2
• Viral hepatitis risk factors: IV drug use, transfusions, sexual exposure, tattoos 1

Initial Diagnostic Workup

Order the following serologic tests immediately 1, 2:

First-tier essential tests:

• Hepatitis A IgM, Hepatitis B surface antigen (HBsAg) and core antibody IgM, Hepatitis C antibody
• Fasting glucose or HbA1c, lipid panel (assess for metabolic syndrome)
• Iron studies: ferritin, transferrin saturation (screen for hemochromatosis)
• Abdominal ultrasound to assess for steatosis, biliary dilatation, liver morphology 1, 2

Second-tier if first-tier negative:

• Antinuclear antibody (ANA), anti-smooth muscle antibody, immunoglobulins (autoimmune hepatitis)
• Ceruloplasmin if age < 40 years (Wilson's disease)
• Alpha-1 antitrypsin level and phenotype if emphysema or family history present 2

Prognostic Considerations

The degree of ALT elevation matters for risk stratification: While your ALT of 142 U/L represents mild-moderate elevation (< 5× upper limit of normal), studies demonstrate that any persistent ALT elevation above true healthy normals (29-33 U/L for males, 19-25 U/L for females) associates with increased liver-related mortality 2, 4. The AST level of 61 U/L, while elevated, remains below the 2× upper reference limit threshold where 10-year major adverse liver outcome risk exceeds 5% 4.

Critical Pitfalls to Avoid

• Don't dismiss as "mild elevation": Even modest aminotransferase elevations warrant systematic evaluation, as they may represent early-stage progressive liver disease 2
• Don't overlook supplements and herbals: Patients often don't consider these "real medications" but they're common hepatotoxins 1
• Don't assume Gilbert's syndrome: The direct bilirubin fraction (0.3 mg/dL) represents 33% of total bilirubin, which is normal; Gilbert's would show predominantly unconjugated hyperbilirubinemia 3
• Don't ignore the albumin: While 3.6 g/dL is technically normal, it's at the lower end and warrants monitoring, as albumin reflects hepatic synthetic function 3

Follow-Up Strategy

If initial workup is unrevealing 1:

• Repeat liver tests in 3-6 months to determine if elevation is persistent or transient
• Chronic elevation (≥ 6 months) typically warrants liver biopsy or non-invasive fibrosis assessment (FIB-4, elastography) to stage disease and guide management
• More expeditious evaluation is warranted if aminotransferases rise further, synthetic function deteriorates (albumin drops, INR rises), or symptoms develop

The hepatocellular pattern with preserved synthetic function suggests this is likely early-stage, potentially reversible liver injury rather than advanced disease, making prompt identification and removal of the causative agent critical 5, 2.